Gregory J. German

Gregory J. German

Auto-generated profile, based on publicly available information

Gregory J. German

Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada; European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Non-Traditional Antibacterial Therapy (ESGNTA); Unity Health Toronto, St. Joseph's Health Centre and Li Ka Shing Knowledge Institute, Toronto, Ontario, Canada

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2023 in PHAGE: Therapy, Applications, and Research
Verified
Journal Article
Open access
AAAmany M. Al-Anany
Amany M. Al-Anany
PHPayton B. Hooey
Payton B. Hooey
JCJonathan D. Cook
Jonathan D. Cook
LBLori L. Burrows
Lori L. Burrows
JMJulia Martyniuk
Julia Martyniuk
GGGreg J. German
Greg J. German
Urinary tract infections (UTIs) are a problem worldwide, affecting almost half a billion people each year. Increasing antibiotic resistance and limited therapeutic options have led to the exploration of alternative therapies for UTIs, including bacteriophage (phage) therapy. This systematic review aims at evaluating the efficacy of phage therapy in treating UTIs. We employed a comprehensive search strategy for any language, any animal, and any publication date. A total of 55 in vivo and clinical studies were included. Of the studies, 22% were published in a non-English language, 32.7% were before the year 1996, and the rest were after 2005. The results of this review suggest that phage therapy for UTIs can be effective; more than 72% of the included articles reported microbiological and clinical improvements. On the other hand, only 5 randomized controlled trials have been completed, and case reports and case series information were frequently incomplete for analysis. Overall, this comprehensive systematic review identifies preliminary evidence supporting the potential of phage therapy as a safe and viable option for the treatment of UTIs.

23 March 2022 in Scientific Reports
Verified
Journal Article
Open access
PDF file
CRCharlene Ranadheera
Charlene Ranadheera
GGGreg J. German
Greg J. German
LSLaura Steven
Laura Steven
DEDale Eung
Dale Eung
DLDmytro Lyubashenko
Dmytro Lyubashenko
CCCindi Corbett
Cindi Corbett
The COVID-19 pandemic required increased testing capacity, enabling rapid case identification and effective contract tracing to reduce transmission of disease. The BioFire FilmArray is a fully automated nucleic acid amplification test system providing specificity and sensitivity associated with gold standard molecular methods. The FilmArray Respiratory Panel 2.1 targets 22 viral and bacterial pathogens, including SARS-CoV-2 and influenza virus. While each panel provides a robust output of information regarding pathogen detection, the specimen throughput is low. This study evaluates the FilmArray Respiratory Panel 2.1 using 33 pools of contrived nasal samples and 22 pools of clinical nasopharyngeal specimens to determine the feasibility of increasing testing capacity, while maintaining detection of both SARS-CoV-2 and influenza virus. We observed 100% detection and 90% positive agreement for SARS-CoV-2 and 98% detection and 95% positive agreement for influenza viruses with pools of contrived or clinical specimens, respectively. While discordant results were mainly attributed to loss in sensitivity, the sensitivity of the pooling assay was well within accepted limits of detection for a nucleic acid amplification test. Overall, this study provides evidence supporting the use of pooling patient specimens, one in four with the FilmArray Respiratory Panel 2.1 for the detection of SARS-CoV-2 and influenza virus.

6 September 2025 in International Journal of Antimicrobial Agents
Verified
Journal Article
Open access
RARiley D. Alvarez
Riley D. Alvarez
CÅChristine Årdal
Christine Årdal
ACAnnika Y. Classen
Annika Y. Classen
TNTobi E. Nagel
Tobi E. Nagel
PCPieter-Jan Ceyssens
Pieter-Jan Ceyssens
GGGreg J. German
Greg J. German
With antimicrobial resistance as a worldwide public health concern, bacteriophage (phage) therapy (PT) may help treat bacterial infections. However, given its particularities compared with traditional small molecule drugs, there are variations in how it is regulated worldwide. Regulators are key players governing PT, yet their perspectives have been largely unexplored. Here, we present findings from the first international survey aimed at capturing the current and future landscape of PT according to regulators. We distributed the survey to members of the second European Union-Joint Action on Antimicrobial Resistance and Healthcare-Associated Infections and individually contacted regulators. Results were collected between October 30, 2024 and March 26, 2025. Twenty-three respondents represented twenty-one countries across Europe, North America, Africa, and Oceania (response rate 67%). Phages or PT were reported as being mentioned in only three national action plans (13%). Nearly half of the respondents declared no prior involvement in phage-related regulatory processes in the past decade, and 32% were uncertain if phages have ever been used therapeutically in their country. Among those who were aware of previous in-country PT, single-use cases dominated, with 27% of respondents acknowledging this as a resource burden (compared to other regulatory applications). Some regulators reported that adapted frameworks are being explored for PT, while one indicated a new framework was being considered. These results underscore that globally major steps aimed at increasing awareness, engagement, and collaboration on best practices amongst regulators are still required to clarify and improve clinical access pathways for PT.

8 September 2025 in International Journal of Antimicrobial Agents
Verified
Journal Article
Open access
JCJonathan D. Cook
Jonathan D. Cook
PHPayton B. Hooey
Payton B. Hooey
KSKeiko C. Salazar
Keiko C. Salazar
JCJustin R. Clark
Justin R. Clark
UJUmesh Jain
Umesh Jain
GGGreg J. German
Greg J. German
Chronic urinary tract infections are persistent bacterial infections with the potential to drive antibiotic resistance. Like other persistent bacterial infections, intracellular bacterial reservoirs and biofilm formation hinder the clearance of pathogens despite long courses of antibiotic therapy. New strategies for treatment of these persistent infections are needed. Here we describe the results of an open-label individual patient study using bacteriophage therapy to treat a chronic urinary tract infection in an immunocompetent 72-year-old woman without underlying urolithiasis or indwelling devices. We co-administered HP3.1, HP3, and ES19 bacteriophages with demonstrated in vitro activity via bladder instillation, orally, and as a topical formulation. The primary outcome was safety and tolerability of the treatment. Adverse events were monitored through daily symptom logs and laboratory analysis of blood samples obtained throughout the study. We found that the treatment was safe and well tolerated with no serious adverse events reported. No adverse events were deemed related to the study material. The secondary outcomes were clinical and microbiological efficacy as monitored through daily symptom logs and standard urine culture, respectively. Two weeks after initial clinical improvement, her condition relapsed and culture was consistent with previous isolates. Treatment with ertapenem following bacteriophage therapy led to sustained clinical and microbiologic cure. Exploratory analysis through whole genome sequencing of pre- and post-treatment isolates identified mutations in genes associated with adhesion and evasion that may influence virulence and promote clearance. These results inform expanded randomized clinical trials and support the growing literature that bacteriophage therapies are safe and effective.

1 September 2024 in PHAGE: Therapy, Applications, and Research
Verified
Journal Article
Open access
GGGregory J. German
Gregory J. German
JDJames V. DeGiulio
James V. DeGiulio
JRJolene Ramsey
Jolene Ramsey
AKAndrew M. Kropinski
Andrew M. Kropinski
RMRajeev Misra
Rajeev Misra
Introduction: TLS is a virulent bacteriophage of Escherichia coli that utilizes TolC and lipopolysaccharide as its cell surface receptors. Methods: The genome was reannotated using the latest online resources and compared to other T1-like phages. Results: The TLS genome consists of 49,902 base pairs, encoding 86 coding sequences that display considerable sequence similarity with the T1 phage genome. It also contains 18 intergenic 21-base long repeats, each of them upstream of a predicted start codon and in the direction of transcription. Data revealed that DNA packaging occurs through the pac site-mediated headful mechanism. Conclusions: Based on sequence analysis of its genome, TLS belongs to the Drexlerviridae family and represents the type member of the Tlsvirus genus.

22 September 2025 in International Journal of Antimicrobial Agents
Verified
Journal Article
Open access
RARiley D Alvarez
Riley D Alvarez
EFEmma Finlayson-Trick
Emma Finlayson-Trick
Ruby CY LinRuby CY Lin
Ruby CY Lin
GGGreg J German
Greg J German
Phage therapy is a promising tool to combat the global threat of antimicrobial resistance. Clinicians, as part of interdisciplinary teams, play an integral role in identifying patients for therapy, delivering phages, and monitoring treatment outcomes and safety. As such, in the context of rapidly evolving regulatory landscapes, clinician insight is crucial for advancement of phage therapy. In this study, we describe the first published international anonymized survey aimed at identifying attitudes and experiences of clinicians and healthcare professionals towards phage therapy. We distributed the survey to participants in the Global Clinical Phage Rounds, a network of >300 phage clinicians, health professionals, and scientists, from October 15, 2024 - January 30, 2025. Thirty respondents representing North America, Europe, Oceania, Africa, and Asia completed the survey (response rate 9.6%). The majority of respondents were very well-informed about phage therapy and 93% would consider enrolling their patients in phage therapy randomized controlled trials. Respondents identified Pseudomonas aeruginosa, Klebsiella species, and Staphylococcus aureus as priority organisms and bone/joint, respiratory, and urinary tract infections as priority syndromes. Respondents had concerns about clinical use evidence, regulatory barriers, and accessing phage. Twenty respondents reported experience with phage therapy, so answered additional questions. These respondents acquired phages from sources like phage banks, industry, and importation from other countries. Respondents delivered phage therapy primarily in single-use cases via parenteral/intravenous, topical, or inhalation routes. Experienced respondents endorsed combinations of monitoring before, during, and/or after phage therapy. These results serve as a guiding initiative to improve phage therapy integration in healthcare.